| [1] |
Hong Kong Special Administrative Region. Statistics on 5th wave of COVID-19. 2022. https://www.coronavirus.gov.hk/chi/5th-wave-statistics.html. [2022-3-19]. (In Chinese).
|
| [2] |
Xie RP, Edwards KM, Adam DC, Leung KSM, Tsang TK, Gurung S, et al. Resurgence of Omicron BA.2 in SARS-CoV-2 infection-naive Hong Kong. Nat Commun. 2023;14(1):2422.
|
| [3] |
Wikipedia. COVID-19 pandemic in Hong Kong. 2020. https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Hong_Kong.
|
| [4] |
www.chinanews.com. Central government gives full support to help Hong Kong get out of the "epidemic" as soon as possible. 2022. https://www.chinanews.com.cn/ga/2022/04-21/9735577.shtml. [2022-4-21]. (In Chinese).
|
| [5] |
Mahase E
. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ
2021
;
375
:
n2713
.
|
| [6] |
Blavatnik School of Government. COVID-19 government response tracker. 2020. https://www.bsg.ox.ac.uk/research/covid-19-government-response-tracker. [2022-8-1].
|
| [7] |
The Government of the Hong Kong Special Administrative Region. https://www.coronavirus.gov.hk/chi/index.html. [2022-8-1]. (In Chinese).
|
| [8] |
Gianino MM, Nurchis MC, Politano G, Rousset S, Damiani G
. Evaluation of the strategies to control COVID-19 pandemic in four European countries. Front Public Health
2021
;
9
:
700811
.
|
| [9] |
Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. https://covid19.mhlw.go.jp/en/. [2022-5-1].
|
| [10] |
Liu Y, Rocklöv J
. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med
2022
;
29
(
3
):
taac037
.
|
| [11] |
Thakur V, Ratho RK
. OMICRON (B. 1.1.529): a new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol
2022
;
94
(
5
):
1821
−
4
.
|
| [12] |
World Health Organization. EG.5 initial risk evaluation, 9 August 2023. 2023. https://www.who.int/docs/default-source/coronaviruse/09082023eg.5_ire_final.pdf?sfvrsn=2aa2daee_1. [2023-8-9].
|
| [13] |
Kim S
. COVID-19 drug development. J Microbiol Biotechnol
2022
;
32
(
1
):
1
−
5
.
|
| [14] |
Ashburn TT, Thor KB
. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Dis
2004
;
3
(
8
):
673
−
83
.
|
| [15] |
Wang B, Li HJ, Cai MM, Lin ZX, Ou XF, Wu SH, et al
. Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single Centre, Randomised, double-blind, placebo-controlled trial. eClinicalMedicine
2023
;
63
:
102189
.
|